IIL in the News

Be in-the-know of the latest advances in the organisation.

Indian Immunologicals unveils indigenously developed Hepatitis A vaccine

19 January 2024

MRP set at ₹2,150 per shot for the two-dose Havisure that has been launched after years of R&D, extensive clinical trials as well as a non-inferiority study, says MD K Anand Kumar

Indian Immunologicals launches measles and rubella vaccine for children

25 November 2023

Developed in partnership with Polyvac Institute of Vietnam, IIL launched Mabella vaccine as part of the 25th celebrations of Human Biologicals Institute

IIL launches virtual medical representatives

13 February 2023

eMOz will eventually be acquiring AI avatars of sales representatives to interact and assist physicians in one of its kind experiences

Indian Immunologicals set to roll out Hepatitis A and MR vaccines in 2023

06 February 2023

Hyderabad-based vaccine manufacturer Indian Immunologicals Limited (IIL) is all ready to launch vaccines for Hepatitis A (Hep A) and for Measles and Rubella (MR) in 2023.

IIL deploys drones to transport animal vaccines

15 November 2022

Drone delivery of vaccines not only reaches remote terrains faster but also helps in providing vaccines on time for the protection of livestock

Indian Immunologicals to set up ₹700 crore plant in Hyderabad’s Genome Valley

11 October 2022

A veterinary vaccine facility, it will grow Genome Valley’s presence, make jabs for FMD, other emerging diseases, create jobs for 750 people National Dairy Development Board subsidiary Indian Immunologicals (IIL) will be investing about ₹700 crore to set up a new animal vaccine manufacturing facility in Genome Valley, Hyderabad.

Indian Immunologicals invests Rs 700 Cr in new animal vaccine facility in Hyderabad

11 October 2022

Indian Immunologicals Limited (IIL) has announced that the company will invest about Rs 700 crore to set up a new animal vaccine manufacturing facility in Genome Valley, Hyderabad - the “Vaccine Hub of the World”, to meet the vaccine security of the nation against economically important diseases such as Foot and Mouth disease (FMD) and other emerging diseases. The facility will create total employment for around 750 people.

INDIA’S LEADING VACCINE MAKER, INDIAN IMMUNOLOGICALS LTD, EXPANDS NEW ZEALAND OPERATIONS

21 July 2022

Dr. K. Anand Kumar, Managing Director, Indian Immunologicals Ltd expresses his views with Indian Weekender, on IIL's expansion of its subsidiary, Pristine Biologicals in Dargaville North Island, New Zealand.

Indian Immunologicals Ltd to expand New Zealand Operations

12 July 2022

The facility was inaugurated by Shri Meenesh C. Shah, Chairman of Indian Immunologicals Ltd and National Dairy Development Board, in the presence of Dr. Jason Smith, the Hon Mayor of Dargaville, Dr. K. Anand Kumar, Managing Director, IIL, Dr. Vijay Dasari, GM and Director, Pristine Biologicals (NZ) Limited and many dignitaries

IIL's subsidiary Pristine Biologicals NZ inaugurates new sterile filtered serum manufacturing facility in Dargaville, New Zealand

12 July 2022

Pristine Biologicals NZ Ltd, a subsidiary of Indian Immunologicals Ltd (IIL) - one of the largest producers of vaccines in India, which belongs to the National Dairy Development Board (NDDB) in India has inaugurated a new facility in Dargaville, New Zealand today for the production of sterile filtered serum.

Indian Immunologicals Ltd To Expand New Zealand Operations

12 July 2022

The requirement for bovine serum from New Zealand for use in biologics manufacture has gone up many folds and to meet the demands of the world markets, it is important to augment the capacities and also bring in more value-added products, the company feels

Pristine Biologicals inaugurates New Sterile Filtered Serum manufacturing facility in New Zealand’s Dargaville

12 July 2022

The requirement for bovine serum from New Zealand for use in biologics manufacture has gone up many folds and to meet the demands of the world markets, it is important to augment the capacities and also bring in more value-added products, the company claimed.

Indian Immunologicals to expand New Zealand operations

12 July 2022

Indian Immunologicals Limited (IIL), the vaccine maker under the National Dairy Development Board (NDDB), has announced expansion of operations in New Zealand through its subsidiary Pristine Biologicals NZ.

Pristine Biologicals inaugurates new facility in Dargaville, NZ

12 July 2022

The facility was established in Dargaville, Kaipara District in 2015 for the production and supply of pharmaceutical grade bovine serum used to produce many vaccines and is considered a very successful venture. It is pertinent to note that the serum from New Zealand and Australia has premium value since those countries are free from OIE listed diseases.

IIL's subsidiary Pristine Biologicals NZ opens serum manufacturing facility in Dargaville, NZ

12 July 2022

Pristine Biologicals NZ, a subsidiary of Indian Immunologicals Ltd (IIL) has inaugurated a new facility in Dargaville for the production of sterile-filtered serum. The facility was inaugurated by Meenesh C Shah, Chairman of Indian Immunologicals and National Dairy Development Board, in the presence of Dr Jason Smith, the Mayor of Dargaville, Dr K Anand Kumar, MD, IIL, Dr Vijay Dasari, GM and Director, Pristine Biologicals (NZ) and many dignitaries.

Indian Immunologicals launches Goat Pox Vaccine

29 December 2021

Indian Immunologicals Ltd (IIL) has launched Goat Pox Vaccine (Raksha Goat Pox) which is expected to help Control of Goat Pox disease.

IIL donates oxygen generation plant to TIMS, Gachibowli

13 December 2021

Indian Immunologicals Limited (IIL) donated a PSA Oxygen Generation Plant to the Telangana Institute of Medical Sciences (TIMS), Gachibowli for service to patients in need of oxygen support.

The pandemic’s silent saviours

01 October 2021

We salute the scientists who’ve been working behind the scenes, combating the coronavirus

Govt lauds Indian Immunologicals for producing Covid-19 vaccine drug substance in record time

24 September 2021

Hyderabad: Union Fisheries, Animal Husbandry, and Dairying minister Parshottam Rupala lauded the efforts of Indian Immunologicals Limited (IIL) for its ability to roll out Covid-19 vaccine drug substance in record time.

Union Minister Parshottam Rupala lauds IIL for producing COVID-19 drug substance in record time

24 September 2021

New Delhi [India], September 24 (ANI): Union Fisheries, Animal Husbandry, and Dairying Minister, Parshottam Rupala lauded the efforts of Indian Immunologicals Limited (IIL) for their ability to roll out the COVID-19 vaccine drug substance in record time.

Govt lauds IIL, BBIL's effort in COVID-19 vaccine production

24 September 2021

Union Fisheries, Animal Husbandry, and Dairying Minister, Parshottam Rupala hands over COVID-19 drug substance made at IIL to Dr Krishna Ella, CMD, BBIL

Indian Immunologicals to ramp up production of input for Covaxin

24 September 2021

This was disclosed by the Hyderabad-based IIL during the visit of Union Minister Parshottam Rupala

Scroll to Top